Novel Diabetes Drug Effective in Trial (CME/CE)

(MedPage Today) -- The investigational SGLT2 inhibitor empagliflozin lowers HbA1c as well as the widely used DPP-4 inhibitor sitagliptin (Januvia), and may work better than the incretin stimulator among patients with worse disease control, researchers found.
Source: MedPage Today Endocrinology - Category: Endocrinology Source Type: news